C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +6.38% and +72.77%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?